Skip to main content

Table 6 Comparison of progression-free survival (months) after autologous stem cell transplantation calculated using Kaplan–Meier analysis and the groups with the log-rank test

From: Survival in patients with multiple myeloma: evaluation of possible associations with bone marrow fibrosis and investigation of factors independently associated with survival

  n Progression Mean ± Standard Error (95% CI) p
Progression-free survival times 32 30 25.92 ± 3.66 (18.75–33.08) N/A
Age     
 < 60 20 18 28.87 ± 5.02 (19.04–38.70) 0.238
 ≥ 60 12 12 21.08 ± 5.09 (11.11–31.06)  
Sex     
 Male 18 18 21.83 ± 4.79 (12.45–31.22) 0.202
 Female 14 12 31.35 ± 5.68 (20.22–42.48)  
Comorbidity     
 No 16 16 24.13 ± 4.60 (15.11–33.14) 0.401
 Yes 16 14 28.18 ± 5.91 (16.60–39.76)  
Type     
 Heavy chain 24 23 25.31 ± 4.71 (16.07–34.55) 0.815
 Light chain 8 7 26.29 ± 2.71 (20.98–31.59)  
Stage     
 Others 10 10 29.00 ± 6.08 (17.08–40.92) 0.642
 Stage III (A/B) 21 19 25.53 ± 4.71 (16.30–34.76)  
Lytic lesion     
 No 5 5 36.60 ± 10.91 (15.21–57.99) 0.190
 Yes 16 15 23.75 ± 5.44 (13.09–34.42)  
Plasmacytoma     
 No 18 16 29.85 ± 5.35 (19.37–40.33) 0.169
 Yes 14 14 21.00 ± 4.78 (11.63–30.38)  
Hypercalcemia     
 No 24 22 29.58 ± 4.54 (20.69–38.47) 0.021
 Yes 5 5 11.40 ± 4.80 (1.99–20.81)  
High creatinine (> 2)     
 No 23 22 27.04 ± 4.14 (18.93–35.16) 0.772
 Yes 9 8 22.83 ± 8.07 (7.01–38.66)  
Bone marrow fibrosis level     
 0 6 6 22.17 ± 3.58 (15.15–29.19) 0.479
 1–4 25 23 26.32 ± 4.60 (17.31–35.33)  
  1. p values marked with bold indicate statistically significant differences between the groups
  2. CI, confidence interval